Filter
Sort by
View
81 case(s) found.

The OxySacklers: Making Money - the Wrong Way

By  Morten Bennedsen,  Brian Henry
Add to cart new
The Sackler family and their 100%-owned company, Purdue Pharma, produced OxyContin pills by the millions, amassing a vast family fortune in the process. Those painkillers were responsible for a devastating opioid epidemic in the United States. For a business family, the “Oxy-Sacklers” are distinguished by their greed and lack of moral compass.

    Published 11 Dec 2023

    Reference 6849

    Length 11 page(s)

    Topic Family Business

    Region North America

    Industry Pharmaceuticals,  Law Practice

    View case

    The OxySacklers: Making Money - the Wrong Way

    By  Morten Bennedsen,  Brian Henry
    Add to cart new
    The Sackler family and their 100%-owned company, Purdue Pharma, produced OxyContin pills by the millions, amassing a vast family fortune in the process. Those painkillers were responsible for a devastating opioid epidemic in the United States. For a business family, the “Oxy-Sacklers” are distinguished by their greed and lack of moral compass.
      View case

      Easier Together: Zirq Solutions’ Ecosystem Approach to Recycling Insulin Pens

      By  Clara Carrera,  Michael Olenick,  Luk Van Wassenhove,  Atalay Atasu
      Add to cart new
      The case describes how the Danish company Zirq Solutions, a subsidiary of Norwegian NG Group, brought circular economy thinking to the pharmaceutical industry.

        Published 05 Mar 2024

        Reference 6834

        Length 10 page(s)

        Topic Responsibility

        Region Europe

        Industry Pharmaceuticals,  Renewables & Environment

        View case

        Easier Together: Zirq Solutions’ Ecosystem Approach to Recycling Insulin Pens

        By  Clara Carrera,  Michael Olenick,  Luk Van Wassenhove,  Atalay Atasu
        Add to cart new
        The case describes how the Danish company Zirq Solutions, a subsidiary of Norwegian NG Group, brought circular economy thinking to the pharmaceutical industry.
          View case

          The Shire/Baxalta Acquisition

          By  Philipp Meyer-Doyle,  Massimo Massa,  Siddharth Poddar
          Add to cart
          The case describes the lead-up to the offer to acquire Baxalta Inc by Shire PLC in the summer of 2015, weeks after Baxalta was spun out of Baxter’s BioScience business. The setting is the biopharmaceutical sector – the fastest-growing in the global pharmaceutical industry in 2014, when M&As reached a record $219.4 billion.

            Published 17 Jan 2022

            Reference 6690

            Length 19 page(s)

            Topic Strategy

            Region Global

            Industry Pharmaceuticals

            View case

            The Shire/Baxalta Acquisition

            By  Philipp Meyer-Doyle,  Massimo Massa,  Siddharth Poddar
            Add to cart
            The case describes the lead-up to the offer to acquire Baxalta Inc by Shire PLC in the summer of 2015, weeks after Baxalta was spun out of Baxter’s BioScience business. The setting is the biopharmaceutical sector – the fastest-growing in the global pharmaceutical industry in 2014, when M&As reached a record $219.4 billion.
              View case

              Novartis: Building a Sustainable Business at the Bottom of the Pyramid

              By  Amitava Chattopadhyay,  Reinhard Angelmar
              Add to cart popular extra
              Inspired by C.K. Prahalad’s “The Fortune at the Bottom of the Pyramid”, Novartis was exploring ways to build a sustainable business for the BOP in India that would improve access to healthcare for the poor while being financially profitable, unlike Novartis's traditional philanthropic and corporate social responsibility approaches.

                Published 26 Mar 2018

                Reference 6388

                Length 15 page(s)

                Topic Responsibility

                Region Asia

                Industry Pharmaceuticals

                View case

                Novartis: Building a Sustainable Business at the Bottom of the Pyramid

                By  Amitava Chattopadhyay,  Reinhard Angelmar
                Add to cart popular extra
                Inspired by C.K. Prahalad’s “The Fortune at the Bottom of the Pyramid”, Novartis was exploring ways to build a sustainable business for the BOP in India that would improve access to healthcare for the poor while being financially profitable, unlike Novartis's traditional philanthropic and corporate social responsibility approaches.
                  View case

                  Turing Pharmaceuticals: Fair Profit or Price Gouging in the Drug Industry?

                  By  N. Craig Smith,  Erin McCormick
                  Add to cart
                  This case examines how a drug price increase by one small company, Turing Pharmaceuticals, became the focal point of a controversy that engulfed the entire drug industry. Turing’s decision to raise the price of its anti-infection drug Daraprim, from $13.50 to $750 per dose, is emblematic of the debate about the responsibilities of pharmaceutical companies and business more generally.

                    Published 29 May 2017

                    Reference 6253

                    Length 20 page(s)

                    Topic Responsibility

                    Region North America

                    Industry Pharmaceuticals

                    View case

                    Turing Pharmaceuticals: Fair Profit or Price Gouging in the Drug Industry?

                    By  N. Craig Smith,  Erin McCormick
                    Add to cart
                    This case examines how a drug price increase by one small company, Turing Pharmaceuticals, became the focal point of a controversy that engulfed the entire drug industry. Turing’s decision to raise the price of its anti-infection drug Daraprim, from $13.50 to $750 per dose, is emblematic of the debate about the responsibilities of pharmaceutical companies and business more generally.
                      View case

                      Patient Access to Pulmolive in China

                      By  Reinhard Angelmar,  Ebru Tekin Turhan
                      Add to cart
                      An international pharmaceutical company must decide on the pricing and access strategy for the first targeted medicine approved in China to treat advanced non-small cell lung cancer, a high mortality condition, in ALK-positive patients.

                        Published 20 Aug 2021

                        Reference 6138

                        Length 5 page(s)

                        Topic Marketing

                        Region Asia

                        Industry Pharmaceuticals

                        View case

                        Patient Access to Pulmolive in China

                        By  Reinhard Angelmar,  Ebru Tekin Turhan
                        Add to cart
                        An international pharmaceutical company must decide on the pricing and access strategy for the first targeted medicine approved in China to treat advanced non-small cell lung cancer, a high mortality condition, in ALK-positive patients.
                          View case

                          Arogya Parivar: Novartis' BOP Strategy for Healthcare in Rural India

                          By  Amitava Chattopadhyay,  Anuj Pasrija,  Olivier Jarry,  Jean Wee
                          Add to cart popular extra
                          With the publication of CK Prahalad’s “The Fortune at the Bottom of the Pyramid” (2005), the poor were suddenly seen as a potential market in the eyes of multinational corporations (MNCs). Although poor, the BOP is a large and growing market.

                            Published 27 Oct 2014

                            Reference 6088

                            Length 27 page(s)

                            Topic Strategy

                            Region Asia

                            Industry Pharmaceuticals

                            View case

                            Arogya Parivar: Novartis' BOP Strategy for Healthcare in Rural India

                            By  Amitava Chattopadhyay,  Anuj Pasrija,  Olivier Jarry,  Jean Wee
                            Add to cart popular extra
                            With the publication of CK Prahalad’s “The Fortune at the Bottom of the Pyramid” (2005), the poor were suddenly seen as a potential market in the eyes of multinational corporations (MNCs). Although poor, the BOP is a large and growing market.
                              View case

                              Growth Strategies in the Pharmaceutical Industry (A)

                              By  Shantanu Bhattacharya,  Sameer Hasija,  Sjiva De Meester
                              Add to cart
                              This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.

                                Published 21 Aug 2015

                                Reference 6074

                                Length 10 page(s)

                                Topic Operations

                                Industry Pharmaceuticals

                                View case

                                Growth Strategies in the Pharmaceutical Industry (A)

                                By  Shantanu Bhattacharya,  Sameer Hasija,  Sjiva De Meester
                                Add to cart
                                This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.
                                  View case

                                  Zoetis, Pfizer's Animal Health Spin-Off (B)

                                  By  Shantanu Bhattacharya,  Sameer Hasija,  Sjiva De Meester
                                  Add to cart
                                  This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.

                                    Published 21 Aug 2015

                                    Reference 6074

                                    Length 6 page(s)

                                    Topic Operations

                                    Industry Pharmaceuticals

                                    View case

                                    Zoetis, Pfizer's Animal Health Spin-Off (B)

                                    By  Shantanu Bhattacharya,  Sameer Hasija,  Sjiva De Meester
                                    Add to cart
                                    This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.
                                      View case

                                      Growth Strategies in the Pharmaceutical Industry (A) (Japanese)

                                      By  Shantanu Bhattacharya,  Sameer Hasija,  Sjiva De Meester
                                      Add to cart extra
                                      This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.

                                        Published 29 Aug 2016

                                        Reference 6074

                                        Length 11 page(s)

                                        Topic Operations

                                        Industry Pharmaceuticals

                                        View case

                                        Growth Strategies in the Pharmaceutical Industry (A) (Japanese)

                                        By  Shantanu Bhattacharya,  Sameer Hasija,  Sjiva De Meester
                                        Add to cart extra
                                        This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.
                                          View case

                                          Pulmocit: Negotiating Pharmaceutical Products with the Government (A) - Mr Simone Moretti (AhaPharma) - Confidential Instructions

                                          By  Horacio Falcao,  Rodrigo Gouveia
                                          Add to cart
                                          This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.

                                            Published 27 Jan 2014

                                            Reference 6033

                                            Length 4 page(s)

                                            Topic Economics & Finance

                                            Region Global

                                            Industry Pharmaceuticals

                                            View case

                                            Pulmocit: Negotiating Pharmaceutical Products with the Government (A) - Mr Simone Moretti (AhaPharma) - Confidential Instructions

                                            By  Horacio Falcao,  Rodrigo Gouveia
                                            Add to cart
                                            This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
                                              View case

                                              Pulmocit: Negotiating Pharmaceutical Products with the Government (B) - Dr Rozentale (Alpenian Government) - Confidential Instructions

                                              By  Horacio Falcao,  Rodrigo Gouveia
                                              Add to cart
                                              This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.

                                                Published 27 Jan 2014

                                                Reference 6033

                                                Length 5 page(s)

                                                Topic Economics & Finance

                                                Region Global

                                                Industry Pharmaceuticals

                                                View case

                                                Pulmocit: Negotiating Pharmaceutical Products with the Government (B) - Dr Rozentale (Alpenian Government) - Confidential Instructions

                                                By  Horacio Falcao,  Rodrigo Gouveia
                                                Add to cart
                                                This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
                                                  View case